Metabolism and excretion of imrecoxib in rat

Xenobiotica

Volumn 36, Issue 5, 2006, Pages 441-455

  Xu, H ^a   Zhang, Y ^a   Sun, Y ^a   Zhang, P ^a   Chu, F ^b   Guo, Z ^b   Zhang, H ^a   Zhong, D ^a,c  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Imrecoxib; Metabolism

Indexed keywords

4' HYDROXYMETHYL 5 HYDROXYLIMRECOXIB; CARBOXYLIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; GLUCURONIDE; IMRECOXIB; UNCLASSIFIED DRUG;

ARTICLE; BILE; CONTROLLED STUDY; DRUG EXCRETION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG URINE LEVEL; FECES; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; OXIDATION-REDUCTION; PYRROLES; RATS; RATS, WISTAR; SULFIDES;

EID: 33745091727     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600595524     Document Type: Article

References (21)

1. Bai AP, Guo ZR, Hu WH, Shen F, Cheng GF. 2001. Design, synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3,4-diaryl-3-pyrrolin-2-ones. Chinese Chemical Letters 12:775-778.
2. Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF. 2004. Imrecoxib: A novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacologica Sinica 25:927-931.
3. Davies NM, Jamali F. 2004. COX-2 selective inhibitors cardiac toxicity: Getting to the heart of the matter. Journal of Pharmacy and Pharmaceutical Sciences 7:332-336.
4. Dogne JM, Supuran CT, Pratico D. 2005. Adverse cardiovascular effects of the coxibs. Journal of Medicinal Chemistry 48:2251-2257.
5. Donnelly MT, Hawkey CJ. 1997. Review article: COX-II inhibitors - a new generation of safer NSAIDS?. Alimentary Pharmacology Therapeutics 11:227-236.
6. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. 1997. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563-582.
7. Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, Geer LA, Halpin RA, Agrawal N, Rodrigues AD. 2001. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metabolism and Disposition 29:813-820.
8. Lane NE. 1997. Pain management in osteoarthritis: The role of COX-2 inhibitors. Journal of Rheumatology 24:20-24.
9. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. 2004. Pharmcokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism and Disposition 32:566-571.
10. Masferrer JL, Zweifel BS, Manning PT, Hauser DS, Leahy KM, Smith WG, Isakson PC, Seibert K. 1994. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proceedings of the National Academy of Sciences, USA 91:3228-3232.
11. Needleman P, Isakson PC. 1997. The discovery and function of COX-2. Journal of Rheumatology 24:9-14.
12. Parente L, Perretti M. 2003. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: Two enzymes in the spotlight. Biochemical Pharmacology 65:153-159.
13. 14C]celecoxib in healthy male volunteers. Drug Metabolism and Disposition 28:308-314.
14. Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E, Guay J. 1997. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Canadian Journal of Physiology and Pharmacology 75:1088-1095.
15. Shen F, Bai AP, Guo ZR, Cheng GF. 2002. Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages. Acta Pharmacologica Sinica 23:762-768.
16. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS. 1998. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis and Rheumatism 41:1591-1602.
17. Smith JM, Willis AL. 1971. Aspirin selectivity inhibitors prostaglandins production in human platelets. Nature: New Biology 231:235-237.
18. Smith WL, Dewitt DL. 1996. Prostaglandin endoperoxide H synthases-1 and -2. Advances in Immunology 62:167-215.
19. Thomas LG. 2005. Increased risk of cardiovascular events with coxibs and NSAIDs. Lancet 365:1538-1539.
20. Vane JR. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology 231:232-235.
21. Yuan JJ, Yang DC, Zhang JY, Bible JRR, Karim A, Findlay JWA. 2002. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib in human. Drug Metabolism and Disposition 30:1013-1021.